BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 21615302)

  • 1. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
    Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
    Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
    Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
    Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
    Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
    Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.
    Magro G; Schiappacassi M; Perissinotto D; Corsaro A; Borghese C; Belfiore A; Colombatti A; Grasso S; Botti C; Bombardieri E; Perris R
    J Pathol; 2003 Jul; 200(3):357-69. PubMed ID: 12845632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
    Wasenius VM; Hemmer S; Kettunen E; Knuutila S; Franssila K; Joensuu H
    Clin Cancer Res; 2003 Jan; 9(1):68-75. PubMed ID: 12538453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
    Jiang XL; Zhang H; Chen YL; Peng L
    Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
    [No Abstract]   [Full Text] [Related]  

  • 7. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
    Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
    J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
    Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
    Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma.
    Luo D; Chen H; Li X; Lu P; Long M; Peng X; Lin S; Tan L; Zhu Y; Ouyang N; Li H
    Int J Oncol; 2017 Oct; 51(4):1209-1218. PubMed ID: 28848996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid precursor protein as a potential marker of malignancy and prognosis in papillary thyroid carcinoma.
    Yang Z; Fan Y; Deng Z; Wu B; Zheng Q
    Oncol Lett; 2012 Jun; 3(6):1227-1230. PubMed ID: 22783423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
    Wu G; Zhou Y; Li T; Guo J; Zhou Z
    J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
    Jia M; Guo Y; Lu X
    Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
    Meng XY; Zhang Q; Li Q; Lin S; Li J
    J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
    Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
    Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis.
    Kim HS; Lee JJ; Do SI; Kim K; Do IG; Kim DH; Chae SW; Sohn JH
    Int J Clin Exp Pathol; 2015; 8(5):5695-701. PubMed ID: 26191283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression profiles of mucin antigens in salivary gland mucoepidermoid carcinoma: MUC4- and MUC6-negative expression predicts a shortened survival in the early postoperative phase.
    Honjo K; Hiraki T; Higashi M; Noguchi H; Nomoto M; Yoshimura T; Batra SK; Yonezawa S; Semba I; Nakamura N; Tanimoto A; Yamada S
    Histol Histopathol; 2018 Feb; 33(2):201-213. PubMed ID: 28649694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents.
    Patel A; Straight AM; Mann H; Duffy E; Fenton C; Dinauer C; Tuttle RM; Francis GL
    J Endocrinol Invest; 2002 May; 25(5):403-8. PubMed ID: 12035934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
    Zhang M; Wu W; Gao M; Fei Z
    Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
    Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
    J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.